Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Frac... (n infections as well as infections of th...)

HOME >> MEDICINE >> TECHNOLOGY

Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial

Date:11/5/2011

n infections, as well as infections of the abdomen, urinary tract and ear, were more frequent in patients treated with Prolia. Patients should be advised to seek prompt medical attention if they develop signs or symptoms of severe infection, including cellulitis. Endocarditis was reported more frequently in the Prolia-treated patient group. Epidermal and dermal adverse events such as dermatitis, rashes and eczema have been reported. Discontinuation of Prolia should be considered if severe symptoms develop.

Prolia resulted in significant suppression of bone remodeling. The significance of these findings is unknown. The long-term consequences of the degree of suppression of bone remodeling observed with Prolia may contribute to adverse outcomes such as osteonecrosis of the jaw (ONJ), atypical fractures and delayed fracture healing. ONJ has been reported in patients with Prolia. Patients should be monitored for these adverse outcomes. The most common adverse reactions (> 5 percent and more common than placebo) were back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia and cystitis. Pancreatitis has also been reported with Prolia.

Important EU Safety Information

The most common adverse reactions with Prolia were urinary tract infection, upper respiratory tract infection, sciatica, cataracts, constipation, rash and pain in extremity. The most serious adverse reactions were those of skin infections, predominantly cellulitis, reported more commonly in the Prolia group compared with placebo (0.4 percent vs. 0.1 percent) in postmenopausal osteoporosis studies. In breast and prostate cancer studies, serious adverse reactions of skin infection were similar in the Prolia and placebo groups (0.6 percent vs. 0.6 percent). In the Phase 3 placebo-controlled clinical trial in patients with prostate cancer receiving ADT, an imbalance in cataract adverse events was observed with Prolia compared with placebo (4.7 percent vs. 1.2 perce
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
2. Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
3. Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
4. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
5. XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
6. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
7. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
8. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
9. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
10. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
11. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards

Post Your Comments:

(Date:5/22/2013)... Jersey , 22. Mai 2013 /PRNewswire/ ... Fähigkeitsentwicklung und Beratung, gab heute bekannt, dass ... Chris Geraghty , zum Hauptgeschäftsführer ernannt ... Jahre im Industriebereich wo er zahlreiche Führungspositionen ... von Ray Baxter an, der als Kepner-Tregoe ...

(Date:5/22/2013)... 2013 Z-Medica, a leading developer and marketer ... first-ever line of products designed to meet the unique ... ® EMS 4x4 Dressing, QuikClot ® EMS ... Gauze™, all custom-designed to help responders stop bleeding fast ... to a hospital or trauma center. The line includes ...

(Date:5/22/2013)... -- MGT Capital Investments, Inc. (NYSE MKT: MGT) announced today ... Marcum LLP MicroCap Conference on Thursday, May 30, 2013 ... the Grand Hyatt Hotel. Robert Ladd ... and answer questions. (Logo: http://photos.prnewswire.com/prnh/20130409/NY91046LOGO ... begin at 9:30 a.m. EDT. MGT,s latest presentation materials ...

Breaking Medicine Technology:Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 2 Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 3 Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2 MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2 MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3 MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4

[0] Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer [0] Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services [0] MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference

... University of Bari, Italy, concluded that treating patients after ... (SVR) and protects them from liver-related deaths. The purpose ... outcomes of patients posttransplant who underwent antiviral therapy for ... graft. The use in clinical practice ...

... SPRING, Md., Oct. 29 The U.S. Food ... an injectable antibiotic to treat adults with community ... and skin structure infections (ABSSSI), including methicillin-resistant ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ...

Cached Medicine Technology:Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes 2 FDA Approves Teflaro for Bacterial Infections 2 FDA Approves Teflaro for Bacterial Infections 3

Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes FDA Approves Teflaro for Bacterial Infections

(Date:5/22/2013)... (PRWEB) May 22, 2013 On May 16, ... or more on average, a funeral concierge can help families ... other benefits. Funeral Financials announces their top ... household income in the U.S. having dropped 7.3 ... Sentier Research, the average funeral costs 12.6% of an average ...

(Date:5/22/2013)... (PRWEB) May 22, 2013 TWITTER: @the_USO ... Family Tour together, heading to 8 countries in the next 6 ... Street, Cookie Monster and Members of Congress came together to show ... assembled 2,000 USO Care Packages for distribution to our ... celebrate the five-year partnership of Sesame Street and the USO as ...

(Date:5/22/2013)... Zensah® Compression Apparel released a statement ... titled "Breast pain while running affects one-third of ... help." According to the article, a British study surveyed ... suffer from breast pain while running but do not ... , Zensah emphasizes the importance for women to ...

(Date:5/22/2013)... May 22, 2013 Successful Therapy ... Patricia O’Laughlin Psychotherapy in the Silver Lake community ... all ages as progression to existing Parents and ... ages into parenting therapy has always been suggested, ... O’Laughlin Psychotherapy now specializes in all aspects of ...

(Date:5/22/2013)... (PRWEB) May 22, 2013 Twenty student-led ... next year participating in an intensive startup accelerator designed ... products or services and create local jobs as part ... Each year the Edson initiative offers approximately 20 student ... space, mentorship and training to launch their for-profit, more-than-profit ...

[0] Funeral Financials Announces Their Top 3 Reasons to Hire a Funeral Concierge [0] The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC [0] Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners [0] Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children [0] ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort

... the same way it responds to winning money and eating ... brain,s reward circuitry. , "We may be ... Matthew D. Lieberman, UCLA associate professor of psychology and a ... a fair offer activates the same brain circuitry as when ...

... April 21 Committed to the safety and,well-being of ... evaluate the recent concerns of the New Jersey Department ... closing of three playing,fields over suspected high lead levels., ... Davis Lee (Ph.D.,Synthetic Organic Chemistry) assert that there is ...

... rate was lower than with malignancies diagnosed on face, ears, ... most deadly melanoma skin cancers occur on the scalp and ... (UNC) study. , Researchers analyzed 51,704 melanoma cases in the ... melanomas died at 1.84 times the rate of patients with ...

... April 21 Versus,Technology, Inc., (Versus) announces ... Kidney Institute that will combine Versus,Real-time Location ... Glickman Urological & Kidney Institute,s clinical,workflow expertise ... The collaboration will develop and document ...

... costs and ... improve productivity, CHICAGO, April 21 ... annually(1), the amount,these families spend on employer-sponsored health care per year ... and,Talent Survey revealed that the median annual contribution for family,healthcare coverage ...

... for Health(R) Dental Health Center Highlights the Importance of Oral ... ... April 21 National dental insurer,United Concordia today unveiled the ... http://www.unitedconcordia.com, empowering,consumers to take charge of their oral ...

Cached Medicine News:Health News:Brain reacts to fairness as it does to money and chocolate 2 Health News:Experts Agree There is No Scientific Evidence of Health Risks in New Jersey Synthetic Turf Fields 2 Health News:Experts Agree There is No Scientific Evidence of Health Risks in New Jersey Synthetic Turf Fields 3 Health News:Melanomas on Scalp and Neck More Deadly 2 Health News:Versus Technology, Inc. Announces Collaboration with Cleveland Clinic to Create Clinical Patient Flow Model 2 Health News:Family Healthcare Contributions Edge Closer to Full Month's Salary, Says Aon Consulting 2 Health News:Family Healthcare Contributions Edge Closer to Full Month's Salary, Says Aon Consulting 3 Health News:Family Healthcare Contributions Edge Closer to Full Month's Salary, Says Aon Consulting 4 Health News:Family Healthcare Contributions Edge Closer to Full Month's Salary, Says Aon Consulting 5 Health News:United Concordia Launches New Online Dental Health Center 2

Brain reacts to fairness as it does to money and chocolate Experts Agree There is No Scientific Evidence of Health Risks in New Jersey Synthetic Turf Fields Melanomas on Scalp and Neck More Deadly Versus Technology, Inc. Announces Collaboration with Cleveland Clinic to Create Clinical Patient Flow Model Family Healthcare Contributions Edge Closer to Full Month's Salary, Says Aon Consulting United Concordia Launches New Online Dental Health Center

Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....

Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....

Used to introduce balloon, electrode, closed or non-tapered end and other catheters....

Sheath Introducer featuring patented SLIX Valve, rotating collar, kink-resistant cannula and atraumatic tip transitions....

Medicine Products:

FLEXOR CHECK-FLO Introducer Set Large Valve Assembly with Radiopaque Band CHECK-FLO Performer Introducers CHILDRENS HOSPITAL BOSTON MODIFICATION CHECK-FLO PERFORMER INTRODUCER SETS Avanti+ Catheter Sheath Introducer